Glycosylation of HDL-Associated Proteins and Its Implications in Cardiovascular Disease Diagnosis, Metabolism and Function.

Glycosylation of HDL-Associated Proteins and Its Implications in Cardiovascular Disease Diagnosis, Metabolism and Function.
复制标题

DOI:
10.3389/fcvm.2022.928566
复制
发表时间:
2022
影响因子:
3.6
通讯作者:
Zivkovic, Angela M.
Zivkovic, Angela M.
中科院分区:
医学3区
文献类型:
--
作者:
Romo, Eduardo Z.;Zivkovic, Angela M.

文献摘要

参考文献

相似文献

高密度脂蛋白(高密度脂蛋白)颗粒长期以来一直被认为在预防心血管疾病(CVD)中起关键作用,最近被发现携带一系列糖基化蛋白,这种糖基化在高密度脂蛋白的结构、功能和代谢中的重要性开始显现。早期的研究表明,在不同的病理状态下,高密度脂蛋白相关蛋白的糖基化程度不同,这可能是了解它们在这些疾病中的病因学作用的关键,也可能对诊断发展具有重要意义。鉴于糖基化途径的广泛性和特异性,对高密度脂蛋白相关糖基化的研究有可能揭示心血管疾病的新机制和生物标志物。到目前为止,还没有大型研究检验高密度脂蛋白糖基化特征与心血管结局之间的关系。然而,小规模的试点研究提供了有希望的初步证据,表明这种关系可能存在。在这篇综述文章中,我们讨论了关于高密度脂蛋白相关蛋白糖基化的证据的现状,高密度脂蛋白糖基化在心血管疾病诊断中的潜力,糖基化如何影响高密度脂蛋白的功能,以及改变高密度脂蛋白相关蛋白的糖基化以提供治疗价值的可能性。
High-density lipoprotein (HDL) particles, long known for their critical role in the prevention of cardiovascular disease (CVD), were recently identified to carry a wide array of glycosylated proteins, and the importance of this glycosylation in the structure, function and metabolism of HDL are starting to emerge. Early studies have demonstrated differential glycosylation of HDL-associated proteins in various pathological states, which may be key to understanding their etiological role in these diseases and may be important for diagnostic development. Given the vast array and specificity of glycosylation pathways, the study of HDL-associated glycosylation has the potential to uncover novel mechanisms and biomarkers of CVD. To date, no large studies examining the relationships between HDL glycosylation profiles and cardiovascular outcomes have been performed. However, small pilot studies provide promising preliminary evidence that such a relationship may exist. In this review article we discuss the current state of the evidence on the glycosylation of HDL-associated proteins, the potential for HDL glycosylation profiling in CVD diagnostics, how glycosylation affects HDL function, and the potential for modifying the glycosylation of HDL-associated proteins to confer therapeutic value.
DOI: 10.1021/bi300555d
发表时间: 2012-06-12
期刊: Biochemistry
影响因子: 2.9
作者:
Gao X;Yuan S;Jayaraman S;Gursky O
通讯作者: Gursky O
DOI: 10.1016/j.atherosclerosis.2018.11.006
发表时间: 2019-02-01
期刊: ATHEROSCLEROSIS
影响因子: 5.3
作者:
Dittrich, Julia;Beutner, Frank;Ceglarek, Uta
通讯作者: Ceglarek, Uta
DOI: 10.3389/fcvm.2021.700233
发表时间: 2021
影响因子: 3.6
作者:
Abudukeremu A;Huang C;Li H;Sun R;Liu X;Wu X;Xie X;Huang J;Zhang J;Bao J;Zhang Y
通讯作者: Zhang Y
DOI: 10.1161/atvbaha.118.311607
发表时间: 2018-12-01
影响因子: 8.7
作者:
Furtado, Jeremy D.;Yamamoto, Rain;Sacks, Frank M.
通讯作者: Sacks, Frank M.
DOI: 10.2174/1874091x01206010078
发表时间: 2012
期刊: The open biochemistry journal
影响因子: --
作者:
Eren E;Yilmaz N;Aydin O
通讯作者: Aydin O